Fig. 5. Pharmacological inhibition of MDR1/MRP4 boosts UCB effects in human Th17-cells.

Mean ± SEM frequency of CD39⁺ (A) and FOXP3⁺ (B) lymphocytes within UCB, RTV or UCB plus RTV-treated Th17-cells (gated as CD4⁺IL17⁺ lymphocytes) from n=12 HS and n=10 Crohn’s disease patients. Untreated (vehicle) controls are also shown. (C) Mean ± SEM frequency of CD39⁺ and FOXP3⁺ lymphocytes within LPMC-derived Th17-cells isolated from non-inflamed and inflamed bioptic colonic areas (n=9 Crohn’s). Cells were exposed to the same treatments as in (A) and (B). (D) Mean ± SEM % inhibition of IL17 and IFNγ production by CD4⁺CD25⁻ responders in the presence of untreated, UCB, RTV or UCB plus RTV-treated Th17-cells (n=8 HS and n=15 Crohn’s); (E) Mean ± SEM CD39 and (F) FOXP3 MFI of untreated and UCB, RTV or UCB plus RTV-treated Th17-cells under normoxic or hypoxic conditions (n=5 HS and n=5 Crohn’s).

Comparisons were made using one-way ANOVA or Kruskal-Wallis test, followed by Tukey’s or Dunn’s multiple comparison tests. *P≤0.05;**P≤0.01;***P≤0.001.